drugset / Trial / NCT01999920

Vilazodone for Separation Anxiety Disorder

NCT01999920 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether Vilazodone (Viibryd), an SSRI and 5HT1a receptor agonist, is effective in treating Adult Separation Anxiety Disorder over a 12-week treatment course.

Timeline

Start
2013-12
Primary completion
2017-03
Completion
2017-12-30

Outcome

Missed primary endpoint

registry analysis (superiority test); Vilazodone vs Placebo; p = .064; Mixed Models Analysis NCT01999920 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vilazodone Small molecule 40 mg —